# RACIN (NCT03728179)

> RACIN in Patients With Advanced TIL-negative Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03728179
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Centre Hospitalier Universitaire Vaudois
- Conditions: Solid Tumor, Adult
- Interventions: Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib
- Enrollment: 40
- Primary outcome: Phases Ia and Ib: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Primary outcome: Maximum Tolerated dose (MTD) or recommended phase Ib dose of low-dose irradiation for radio-immunotherapy combination (RP1bD).

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=racin-nct03728179